REDHAWK EXPANDS SANDD SALES INFRASTRUCTURE
May 10 2019 - 8:00AM
InvestorsHub NewsWire
REDHAWK EXPANDS
SANDD SALES INFRASTRUCTURE
Lafayette, LA -- May 10, 2019 -- InvestorsHub
NewsWire -- RedHawk Holdings
Corp. (OTC:
IDNG) (“RedHawk” or
the “Company”) announced today that it has entered into a
customer-specific sales representation agreement with Jeeds Health,
Inc., an affiliate of Pharmaceutical Buyers, Inc. ( “PBI” –
www.pharmaceuticalbuyersinc.com
), for the sale of its
SANDD mini (“Sharps and Needle Destruction Device”)
needle destruction devices. The Company believes the agreement will
eventually extend to the SANDD Pro unit when it is offered for sale
later in 2019.
PBI,
a New York-based company headquartered in Long Island, New York,
sources and distributes clinical trial, biologic and specialty
drugs to approximately 285 major pharmaceutical and biotech
companies in the United States and overseas. Through an affiliate,
R&H Pharmacy, PBI distributes prescription, medication,
vitamins, supplements and over-the-counter items to various
wholesalers in the European Union.
PBI
serves an active base of about 285 major pharmaceutical related
companies in the United States and in over 30 other countries in
the branded, generic and biotech/pharmaceutical industry and
include virtually all major generic drug manufacturers. PBI
specializes in sourcing large quantities of drugs while maintaining
confidentiality for generic, biotech and branded drug
manufacturers. PBI believes it has the deepest supply chain in the
market and is often the sole source for critical and
difficult-to-find drugs. PBI prides itself on providing
pharmaceutical drugs of any type and therapeutic area, in any
dosage form and in any quantity wherever they are needed. PBI also
provides standard of care medicine, adjunctive therapies, rescue
medications and ancillary supplies.
With
its extensive pharmaceutical customer base, the Company said it
believes PBI and its affiliate, Jeeds Health, Inc., are well
positioned in the market to offer its
SANDD mini needle
destruction unit to home use
self-injectors.
The
SANDD mini (formerly
known as The Disintegrator™) is a portable, battery operated,
needle destruction device for use at home primarily by diabetics.
The device is intended for the destruction and environmentally
friendly disposal of 27-32 gauge hypodermic needles that are 5/16
to 5/8 inch in length. It can be used with most insulin pens with
disposable insulin syringes from 1/3 to 1 cubic centimeter in
volume. The SANDD mini
is used by diabetics for the safe and environmentally friendly
disposal of needles following their use and is an effective
alternative to hazardous waste needle disposal utilizing sharps
containers.
RedHawk acquired the exclusive rights to the
SANDD Pro™ (the
“SANDD Pro™”) needle incineration technology in
September 2018. With the SANDD Pro™,
the Company’s hypodermic needle incineration capabilities now
include 14-gauge hypodermic needles and higher, up to 8 inch in
length. Additionally, the acquired SANDD Pro™
technology features a portable, rechargeable, battery operated
unit. This portable unit (the “SANDD Pro™
- Portable”) will incinerate as many as 300 needles, ranging in
gauges as thick as 21 gauge and lengths up to 8” on a single
charge. The SANDD Pro™
- Portable is ideal for field use by first responders, home health
care nurses, veterinarians and home use injectors. The
SANDD Pro™ is FDA approved and OSHA
compliant.
The
complete line of SANDD™
products can be used in virtually all home and commercial
applications including hospitals, first responders, a full range of
clinics and primary care physicians, dentists, veterinarians,
retirement and non-acute healthcare facilities. The
SANDD mini™ is currently offered for sale. After
completion of engineering testing and intellectual property
re-design, the Company said it expects to offer the
SANDD Pro™ and the SANDD Pro™
- Portable for sale during 2019.
RedHawk Medical Products, LLC, a wholly-owned
subsidiary of RedHawk, acquired the tangible and intangible
property rights to SANDD and has completed the re-engineering of its
SANDD mini. The Company has received pre-market clearance from the
U.S. Food and Drug Administration for the sale of
SANDD in the United States.
# # #
About RedHawk Holdings
Corp.
RedHawk Holdings Corp., formerly Independence
Energy Corp., is a diversified holding company which, through its
subsidiaries, is engaged in sales and distribution of medical
devices, sales of branded generic pharmaceutical drugs, commercial
real estate investment and leasing, sales of point of entry
full-body security systems, and specialized financial services.
Through its medical products business unit, the Company sells
WoundClot Surgical - Advanced Bleeding Control, the Sharps and
Needle Destruction Device (SANDD™), and the Carotid Artery Digital
Non-Contact Thermometer. Through our United Kingdom based
subsidiary, we manufacture and market branded generic
pharmaceuticals. Our real estate leasing revenues are generated
from various commercial properties under long-term lease.
Additionally, RedHawk’s real estate investment unit holds limited
liability company interest in a commercial restoration project in
Hawaii. The Company’s financial service revenue is from brokerage
services earned in connection with debt placement services. RedHawk
Energy holds the exclusive U.S. manufacturing and distribution
rights for the Centri Controlled Entry System, a unique, closed
cabinet, nominal dose transmission full-body x-ray
scanner.
Cautionary Statement Regarding Forward-Looking
Statements
This
release may contain forward-looking statements. Forward-looking
statements are all statements other than statements of historical
fact. Statements contained in this release that are not historical
facts may be deemed to be forward-looking statements. The words
“anticipate,” “may,” “can,” “plans,” “believes,” “estimates,”
“expects,” “projects,” “targets,” “intends,” “likely,” “will,”
“should,” “to be,” “potential” and any similar expressions are
intended to identify those assertions as forward-looking
statements.
Investors are cautioned that forward-looking
statements are inherently uncertain. Actual performance and results
may differ materially from that projected or suggested herein due
to certain risks and uncertainties. In evaluating forward-looking statements, you
should consider the various factors which may cause actual results
to differ materially from any forward-looking statements including
those listed in the “Risk Factors” section of our latest 10-K
report. Further, the
Company may make changes to its business plans that could or will
affect its results. Investors are cautioned that the Company will
undertake no obligation to update any forward-looking
statements.